A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. [electronic resource]
Producer: 20071004Description: 523-36 p. digitalISSN:- 1352-0504
- Antiviral Agents -- economics
- Belgium
- Computer Simulation
- Cost-Benefit Analysis
- Drug Costs
- Hepacivirus -- growth & development
- Hepatitis C, Chronic -- drug therapy
- Humans
- Interferon alpha-2
- Interferon-alpha -- economics
- Markov Chains
- Middle Aged
- Models, Econometric
- Polyethylene Glycols -- economics
- Quality-Adjusted Life Years
- Recombinant Proteins
- Ribavirin -- economics
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.